<DOC>
	<DOCNO>NCT00813293</DOCNO>
	<brief_summary>The purpose research study determine sorafenib improve effectiveness procedure call radiofrequency ablation treatment hepatocellular cancer . During radiofrequency ablation ( RF ablation ) needle insert tumor tissue heat use kill tumor cell . Sorafenib approve FDA treatment hepatocellular cancer treat surgery . Radiofrequency ablation use treat many type tumor , include hepatocellular cancer . Pre-clinical data suggests sorafenib may improve efficacy RFA . The use sorafenib prior RF ablation study `` investigational '' approve FDA . `` Investigational '' mean combination still study research doctor try find . In study , study doctor hope good understand extent combination sorafenib RFA may do practically successfully . Correlative image tumor study evaluate mechanism action well novel predictor RFA efficacy .</brief_summary>
	<brief_title>Sorafenib Therapy Prior Radiofrequency Ablation Intermediate Sized Hepatocellular Cancer</brief_title>
	<detailed_description>Participants randomize receive either sorafenib placebo ( pill medication ) . Participants take sorafenib placebo Days 1-9 . Radiofrequency ablation perform interventional radiologist Day 10 . On Days 1 9 study participant physical exam blood test perform . A study MRI perform Beth Israel Deaconess Medical Center ( BIDMC ) prior start study medication Day 9 . A tumor biopsy obtain time RFA . A CT scan perform RFA .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Confirmed hepatocellular cancer ( HCC ) pathology NCCN image guideline All HCC stage allow . May liver transplant candidate . At least one tumor ( index tumor ) accurately measure 3.57cm diameter ( long short axis diameter record , one need meet criterion ) baseline image . No prior therapy index tumor No prior systemic treatment HCC within 4 week prior antiVEGF therapy within 8 week study entry . Life expectancy &gt; 8 week . ECOG &gt; =0 1 RFA clinically indicate index tumor . Acceptable overall RFA anesthesia risk . Adequate bone marrow , liver renal function : Hemoglobin &gt; 9.0 g/dl ; Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 ; Platelet count correctable &gt; 50,000/mm3 ; compensate liver function ( ChildTurcottePugh A , B7 B8 ) ; Creatinine &lt; 1.5 time ULN ; INR correctable &lt; 1.5 . Ability take oral medication evidence impaired absorption . Exclusion Criteria Urgent treatment index tumor anticipate . Participants recover adverse event due agent administer 4 week earlier . Participants currently receive study agent . Known brain metastasis History allergic reaction attribute compound similar chemical biologic composition sorafenib . Participants receive medication substance inducer CYP3A4 ( rifampicin , St. John 's wort , phenytoin , carbamazepine , phenobarbital dexamethasone ) metabolized/eliminated predominantly UGT1A1 pathway CYP2B6 CYP2C8 . Decompensated liver disease Uncontrolled hypertension Thrombolic embolic event within past 6 month . Hemorrhage/bleeding event within 4 week Serious nonhealing wound , ulcer , bone fracture . Evidence severe uncorrectable bleed diathesis coagulopathy Major surgery , open biopsy significant traumatic injury within 4 week study entry . Contraindication inability undergo RFA procedure , Contraindication inability undergo image MRI Uncontrolled intercurrent illness Individuals history different malignancy unless diseasefree least 5 year deem Investigator low risk recurrence . Individuals follow cancer eligible diagnose treat within past 5 year : cervical cancer situ , basal cell squamous cell carcinoma skin . HIVpositive individual combination antiretroviral therapy For additional inclusion/exclusion criterion detail contact Study Site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular Cancer</keyword>
	<keyword>HCC</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>radiofrequency ablation</keyword>
	<keyword>RFA</keyword>
	<keyword>sorafenib</keyword>
	<keyword>nexavaar</keyword>
	<keyword>liver direct therapy</keyword>
	<keyword>interventional radiology</keyword>
</DOC>